Technical Analysis for HOOK - HOOKIPA Pharma Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 2.79 | -0.36% | -0.01 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 0.00% | |
| New Downtrend | Bearish | 0.00% | |
| Doji - Bullish? | Reversal | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| New 52 Week Low | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Down 5 Days in a Row | Weakness | 0.00% |
| Alert | Time |
|---|---|
| Up 5% | about 19 hours ago |
| 60 Minute Opening Range Breakout | about 19 hours ago |
| 1.5x Volume Pace | about 21 hours ago |
| Down 3% | about 21 hours ago |
| Fell Below Previous Day's Low | about 21 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 11/07/2024
HOOKIPA Pharma Inc. Description
HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Infectious Diseases Hepatitis B Transplantation Immunodeficiency Hepatitis B Virus Viral Disease Papillomavirus Gilead Sciences Immunotherapeutics Kidney Transplant
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 11.3 |
| 52 Week Low | 2.7 |
| Average Volume | 40,950 |
| 200-Day Moving Average | 6.18 |
| 50-Day Moving Average | 4.00 |
| 20-Day Moving Average | 3.59 |
| 10-Day Moving Average | 3.37 |
| Average True Range | 0.26 |
| RSI (14) | 21.26 |
| ADX | 25.27 |
| +DI | 9.24 |
| -DI | 31.82 |
| Chandelier Exit (Long, 3 ATRs) | 3.41 |
| Chandelier Exit (Short, 3 ATRs) | 3.49 |
| Upper Bollinger Bands | 4.30 |
| Lower Bollinger Band | 2.89 |
| Percent B (%b) | -0.07 |
| BandWidth | 39.25 |
| MACD Line | -0.29 |
| MACD Signal Line | -0.21 |
| MACD Histogram | -0.0856 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.21 | ||||
| Resistance 3 (R3) | 3.23 | 3.11 | 3.14 | ||
| Resistance 2 (R2) | 3.11 | 3.00 | 3.10 | 3.12 | |
| Resistance 1 (R1) | 2.95 | 2.93 | 2.89 | 2.93 | 3.10 |
| Pivot Point | 2.82 | 2.82 | 2.79 | 2.82 | 2.82 |
| Support 1 (S1) | 2.67 | 2.72 | 2.60 | 2.65 | 2.48 |
| Support 2 (S2) | 2.54 | 2.65 | 2.53 | 2.46 | |
| Support 3 (S3) | 2.38 | 2.54 | 2.44 | ||
| Support 4 (S4) | 2.37 |
